Equity Research Healthcare I Biotechnology ARIAD Pharmaceuticals, Inc. Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12 On Friday, December 20, Ariad announced that it has reached agreement wi